C&R Research Inc is a Korea-based company is mainly engaged in the clinical trial agency and drug development business. The Company is mainly engaged in the provision of comprehensive early-stage clinical services in the areas of medical writing, regulatory matters, data management, biostatistics and others. The Company is mainly engaged in the provision of consulting services including initial clinical development, clinical trial development, global clinical trial development and others. In addition, the Company is also engaged in the operation of clinical trial training center.

Employees

510

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 04/06/2026			5-day change	1st Jan Change
550.00 ^KRW	+7.63%		0.00%	-38.89%

30/03	C&R Research Inc wins 11.5 billion won order	RE
06/11	C&R Research Inc. announces Annual dividend, payable on April 13, 2026	CI

Market Cap	3.16TCr 2.06Cr 1.8Cr 1.66Cr 1.55Cr 2.91Cr 194.22Cr 2.93Cr 20Cr 7.68Cr 95Cr 7.72Cr 7.55Cr 331.74Cr	P/E 2024	17.1x	P/E 2025	19.9x
Enterprise Value	2.89TCr 1.88Cr 1.64Cr 1.52Cr 1.42Cr 2.66Cr 177.79Cr 2.68Cr 18Cr 7.03Cr 87Cr 7.06Cr 6.91Cr 303.67Cr	EV / Sales 2024	0.98x	EV / Sales 2025	0.75x
Free-Float	36.73%	Yield 2024	0.86%	Yield 2025	-

30/03	C&R Research Inc wins 11.5 billion won order	RE
06/11	C&R Research Inc. announces Annual dividend, payable on April 13, 2026	CI
22/23/22	C&R Research Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
08/21/08	C&R Research Co., Ltd. completed the acquisition of NH Special Purpose Acquisition 17 Company in a reverse merger transaction.	CI
23/21/23	C&R Research Co., Ltd. signed an agreement to acquire NH Special Purpose Acquisition 17 Company in a reverse merger transaction.	CI
17/20/17	Nh Special Purpose Acquisition 17 Company has completed an IPO in the amount of KRW 12 billion.	CI
01/20/01	Nh Special Purpose Acquisition 17 Company has filed an IPO.	CI

1 day	+7.63%
Current month	-3.34%
1 month	-13.66%
3 months	-32.10%
6 months	-42.53%
Current year	-38.89%

C&R Research Inc. Share Price

Stocks

A359090

KR7359090008

Biotechnology & Medical Research

Valuation: C&R Research Inc.

Chart: C&R Research Inc.

Latest news : C&R Research Inc.

Quotes and Performance

Course Extremes

Managers and Directors: C&R Research Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

1 month	494	647
Current year	494	974
1 year	494	1,178
3 years	494	2,395
5 years	494	2,680
10 years	494	2,680

Manager	Title	Age	Since
Moon-Tae Yoon CEO	Chief Executive Officer	74	08/12/2021
Kyu-Sun Moon DFI	Director of Finance/CFO	49	-
Byeong-in Ahn PSD	President	56	-

Director	Title	Age	Since
Moon-Tae Yoon BRD	Director/Board Member	74	08/12/2021
Jung-Hee Park BRD	Director/Board Member	62	28/10/2021
Byeong-in Ahn BRD	Director/Board Member	56	-

Date	Insider	Type	Quantity	% Market Cap.
22/24/22	Yun-ho Kim	Sell	73,163	0.1290%
23/24/23	Jin-hak Kim	Buy	6,675	0.0118%
23/24/23	Jin-hak Kim	Buy	13,325	0.0236%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
C&R RESEARCH INC.	+7.63%	0.00%	-47.47%	-55.65%	2.06Cr
LONZA GROUP AG	+2.96%	+4.21%	-8.16%	-2.76%	4.32TCr
REVOLUTION MEDICINES, INC.	+2.83%	+9.08%	+326.58%	+569.29%	3.53TCr
BEONE MEDICINES AG	+1.11%	+3.99%	+6.58%	+53.08%	3.02TCr
IQVIA HOLDINGS INC.	+1.77%	-4.61%	+10.15%	-20.16%	2.8TCr
CELLTRION, INC.	-4.75%	-8.29%	+3.90%	+13.88%	2.41TCr
ASCENDIS PHARMA A/S	+3.79%	+2.09%	-	-	1.42TCr
MEDPACE HOLDINGS, INC.	+0.95%	-0.31%	+49.10%	+106.00%	1.3TCr
EUROFINS SCIENTIFIC SE	+2.77%	+4.02%	+9.61%	+15.31%	1.27TCr
IONIS PHARMACEUTICALS, INC.	+1.19%	+4.84%	+103.42%	+93.31%	1.25TCr
Average	+2.02%	-1.40%	+50.41%	+85.81%	2.13TCr
Weighted average by Cap.	+1.43%	-0.72%	+69.29%	+120.89%

	2024	2025
Net sales	5.97TCr 3.88Cr 3.39Cr 3.14Cr 2.93Cr 5.5Cr 366.77Cr 5.54Cr 37Cr 15Cr 180.32Cr 15Cr 14Cr 626.44Cr	6.5TCr 4.23Cr 3.69Cr 3.42Cr 3.19Cr 5.98Cr 399.29Cr 6.03Cr 41Cr 16Cr 196.32Cr 16Cr 16Cr 682Cr
Net income	383.86Cr 24.96L 21.81L 20.17L 18.83L 35.35L 24Cr 35.61L 2.4Cr 93.27L 12Cr 93.71L 91.68L 40Cr	258.55Cr 16.81L 14.69L 13.59L 12.68L 23.81L 16Cr 23.98L 1.61Cr 62.83L 7.81Cr 63.12L 61.75L 27Cr
Net Debt	-767.36Cr -49.9L -43.6L -40.33L -37.64L -70.66L -47Cr -71.18L -4.79Cr -1.86Cr -23Cr -1.87Cr -1.83Cr -81Cr	-267.4Cr -17.39L -15.19L -14.05L -13.12L -24.62L -16Cr -24.8L -1.67Cr -64.98L -8.08Cr -65.28L -63.86L -28Cr